



March 7, 2021

Dear Pharmaceutical Manufacturer:

Magellan Rx Management (MRx), on behalf of **Arkansas Medicaid**, is soliciting supplemental rebate offers in support of the **Arkansas Medicaid Evidence Based Prescription Drug Program Preferred Drug List (PDL)** for the targeted classes listed below which will be reviewed on May 11, 2022. Instructions, timelines, and contact information are listed below.

- Antipsychotics (Oral Agents only)
- Laxatives and Cathartics (Bowel Prep Agents only)
- Penicillamine/Cystine Depleting Agents
- Proton Pump Inhibitors

Preferred products will be selected based on clinical effectiveness and each product's relative value within the therapeutic class. Manufacturers are encouraged to maintain or enhance current offers in order to be in the best position to achieve or retain a preferred PDL status. Supplemental rebate offers may be requested for additional products and/or other therapeutic categories in the future.

Final supplemental rebate offers must be submitted to Provider Synergies LLC, an affiliate of Magellan Medicaid Administration, Inc. through the secure FTP site: <https://secureftp.providersynergies.com/>, by close of business on March 28, 2022. Supplemental rebates will begin to accrue on July 1, 2022 and will have a 3-year term for those drugs selected as preferred, and end June 30, 2025. Please refer to the State Supplemental Rebate Agreement for terms and conditions.

Arkansas Medicaid and Magellan Rx Management thank you for your continued participation and support of this program.

Sincerely,

A handwritten signature in black ink that reads "Cynthia Neuhofer". The signature is written in a cursive, flowing style.

Cynthia Neuhofer, Pharm.D.

